Compare Abeona Therapeutics Inc (ABEO) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Ultra Gold ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while ProShares Ultra Gold ETF trades at $44.92. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | UGL | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $85.62 |
52-Week Low | $4.17 | $33.59 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
UGL trades at $47.09, up 2.04% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, which may indirectly influence gold-related equities.
The outlook is cautious due to bearish technicals and absent financial data. Risks include gold price volatility and macroeconomic factors. Investors should await earnings reports for fundamental insights, as current data is insufficient for a clear investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
